ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,433.76
0.63%
Dow Jones
39,512.84
0.32%
Gold vs US Dollar
2,360.48
0.00%
Brent Oil
82.585
0.00%
Bitcoin
60,931.38
0.22%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. XBiotech Inc (XBIT)

  7. XBiotech Inc (XBIT) News

XBiotech (XBIT)

XBiotech Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:XBIT
DateTimeSourceHeadlineSymbolCompany
10/05/202416:27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XBITXBiotech Inc
07/02/202417:36Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:XBITXBiotech Inc
07/02/202417:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:XBITXBiotech Inc
05/01/202415:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XBITXBiotech Inc
04/01/202414:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XBITXBiotech Inc
04/01/202414:00GlobeNewswire Inc.XBiotech to Begin Constructing New R&D Facility on its 48-acre CampusNASDAQ:XBITXBiotech Inc
04/01/202414:00GlobeNewswire Inc.XBiotech to Begin Constructing New R&D Facility on its 48-acre CampusNASDAQ:XBITXBiotech Inc
14/11/202314:00GlobeNewswire Inc.Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid ArthritisNASDAQ:XBITXBiotech Inc
09/11/202319:41Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XBITXBiotech Inc
26/09/202314:00GlobeNewswire Inc.XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeNASDAQ:XBITXBiotech Inc
30/08/202314:00GlobeNewswire Inc.XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic CancerNASDAQ:XBITXBiotech Inc
11/08/202316:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XBITXBiotech Inc
08/08/202316:47GlobeNewswire Inc.XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialNASDAQ:XBITXBiotech Inc
26/06/202313:48Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
26/06/202313:46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
26/06/202313:43Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
26/06/202313:40Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
23/06/202320:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XBITXBiotech Inc
20/06/202314:20Edgar (US Regulatory)Amended Tender Offer Statement by Issuer (sc To-i/a)NASDAQ:XBITXBiotech Inc
22/05/202314:00GlobeNewswire Inc.FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsNASDAQ:XBITXBiotech Inc
17/05/202314:22Edgar (US Regulatory)Tender Offer Statement by Issuer (sc To-i)NASDAQ:XBITXBiotech Inc
17/05/202314:00GlobeNewswire Inc.XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesNASDAQ:XBITXBiotech Inc
10/05/202320:42Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XBITXBiotech Inc
28/04/202317:38Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:XBITXBiotech Inc
28/04/202317:33Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:XBITXBiotech Inc
15/02/202311:12Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XBITXBiotech Inc
10/02/202317:22Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:XBITXBiotech Inc
10/02/202317:21Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:XBITXBiotech Inc
10/02/202317:21Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:XBITXBiotech Inc
12/01/202315:29Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:XBITXBiotech Inc
 Showing the most relevant articles for your search:NASDAQ:XBIT

Your Recent History

LSE
PET
Petrel Resources
LSE
TERN
Tern
LSE
VAST
Vast Resources
LSE
SCE
Surface Transforms
LSE
SCLP
Scancell
LSE
GKP
Gulf Keystone Petroleum
LSE
POS
Plexus
LSE
BT.A
Bt
LSE
AGL
Angle
LSE
EEE
Empire Metals
LSE
PANR
Pantheon Resources
LSE
OXB
Oxford Biomedica
LSE
ITV
Itv
LSE
GOLD
LSE
SYME
Supply@me Capital
LSE
SRSP
Sirius Petroleum
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved